Meloxicam
Meloxicam
Brand names:Mobic, Vivlodex
A long-acting non-steroidal anti-inflammatory drug (NSAID) with COX-2 preferential activity, providing analgesia and anti-inflammatory effects with reduced platelet inhibition compared to non-selective NSAIDs. Component of the TCCC Combat Wound Medication Pack (CWMP) since 2007 and retained through the 2026 update.
Pharmacology and Actions
Meloxicam inhibits prostaglandin synthesis through preferential blockade of cyclooxygenase-2 (COX-2) over COX-1. This selectivity provides anti-inflammatory and analgesic effects while reducing the platelet aggregation inhibition and gastric mucosal irritation associated with non-selective NSAIDs.
The drug has a long elimination half-life of 15 to 20 hours, supporting once-daily dosing. This is the primary reason meloxicam was selected for CWMP over shorter-acting NSAIDs like ibuprofen or ketorolac. A single 15 mg dose provides 24-hour anti-inflammatory coverage.
Meloxicam is metabolized primarily by hepatic CYP2C9 and CYP3A4. It is highly protein-bound and excreted in urine and feces.
Indications
- Pain and inflammation in mission-capable casualties (TCCC 2026 CWMP)
- Adjunct anti-inflammatory therapy
- Musculoskeletal pain
- Pain control when reduced platelet effect is preferred over non-selective NSAIDs
Absolute Contraindications
- Known meloxicam or NSAID allergy
- Active gastrointestinal bleeding
- Severe renal impairment
- Severe hepatic impairment
- Coronary artery bypass graft (CABG) surgery (perioperative use contraindicated)
- Pregnancy (third trimester)
Precautions and Side Effects
NSAIDs increase the risk of cardiovascular thrombotic events including myocardial infarction and stroke. This risk is dose-dependent and increases with duration of use. Single-dose CWMP use carries minimal CV risk.
Gastrointestinal effects include dyspepsia, gastric irritation, and rarely upper GI bleeding. Risk is reduced compared to non-selective NSAIDs but not eliminated.
Renal effects include reversible decreases in renal blood flow, particularly in volume-depleted casualties. Use caution in casualties with significant blood loss, dehydration, or pre-existing renal disease.
Platelet effect is reduced compared to non-selective NSAIDs. Meloxicam was specifically selected for CWMP because its limited platelet inhibition does not significantly worsen hemorrhage in trauma casualties. Aspirin and other non-selective NSAIDs are not used in tactical analgesia for this reason.
May cause photosensitivity, rash, or rarely Stevens-Johnson syndrome.
Adult Dosing
Single daily dose. Take with the other CWMP components: acetaminophen 1000 to 1300 mg PO every 8 hours and either suzetrigine 50 mg PO every 12 hours (preferred) or moxifloxacin 400 mg PO once daily.
Standard prescribing: 7.5 mg PO once daily, increasing to 15 mg PO once daily as needed. Maximum 15 mg/day Onset: 30 to 60 minutes (analgesic effect)
Pediatric Dosing
Pediatric prescribing (over age 2): 0.125 mg/kg PO once daily, maximum 7.5 mg/day.
Pediatric tactical use is rare. Consult medical control and pediatric protocols. Not typically administered in field settings to pediatric casualties.
Pharmacokinetics
Peak Effect: 4 to 5 hours
Duration: 24 hours (long half-life supports once-daily dosing)
Storage and Handling
Store at room temperature (15 to 30 degrees Celsius). Protect from light and moisture. Tablet form is stable across the operational temperature range typical of tactical environments.
CWMP blister packs containing meloxicam are typically stable for 2 to 3 years from manufacture date. Verify expiration before deployment.
Reconstitution:
Tablet form requires no reconstitution.
TCCC and TECC Role
Meloxicam is the NSAID component of the TCCC CWMP, providing 24-hour anti-inflammatory coverage from a single oral dose. The drug was selected over shorter-acting NSAIDs because its long half-life makes it operationally compatible with the unpredictable timing of casualty evacuation. A casualty who takes meloxicam at the time of injury will still have therapeutic levels onboard 24 hours later, regardless of whether evacuation took 2 hours or 20 hours.
The COX-2 preferential mechanism reduces but does not eliminate platelet inhibition. Casualties with active hemorrhage benefit from this selectivity profile. Non-selective NSAIDs (ibuprofen, naproxen, ketorolac) are avoided in tactical analgesia because their platelet effects can worsen bleeding.
The 2026 TCCC guidelines retain meloxicam unchanged from prior versions. The drug remains a foundational component alongside acetaminophen for mission-capable casualty analgesia.
Meloxicam is one of those drugs whose value comes from what it doesn't do as much as what it does. It provides solid 24-hour anti-inflammatory coverage without the platelet inhibition that makes other NSAIDs unsuitable for trauma. The once-daily dosing simplifies the CWMP regimen and reduces the risk of missed doses during prolonged casualty care.
For tactical providers, the practical takeaway is that meloxicam should be on board within an hour of injury when the casualty can take oral medications. Waiting to administer the CWMP until reaching higher levels of care defeats the purpose. Early multimodal analgesia reduces opioid requirements later in the care continuum.
The drug pairs particularly well with acetaminophen because the two work through different mechanisms. Acetaminophen handles central pain modulation; meloxicam handles peripheral inflammation. The combination provides analgesia that exceeds the additive effect of either drug alone.
Skipping meloxicam in CWMP administration because the casualty is bleeding. The drug was specifically selected for tactical use because of its reduced platelet effect compared to other NSAIDs. The hemorrhage concern that applies to ibuprofen does not apply to meloxicam at CWMP dosing. Trust the doctrine.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Meloxicam
| PO | TCCC 2026 CWMP: 15 mg PO once daily Single daily dose. Take with the other CWMP components: acetaminophen 1000 to 1300 mg PO every 8 hours and either suzetrigine 50 mg PO every 12 hours (preferred) or moxifloxacin 400 mg PO once daily. Standard prescribing: 7.5 mg PO once daily, increasing to 15 mg PO once daily as needed. Maximum 15 mg/day (30 to 60 minutes (analgesic effect)) |